CN105012233B - 一种含有普鲁卡因的用于分娩的组合物及制备方法 - Google Patents
一种含有普鲁卡因的用于分娩的组合物及制备方法 Download PDFInfo
- Publication number
- CN105012233B CN105012233B CN201510519443.6A CN201510519443A CN105012233B CN 105012233 B CN105012233 B CN 105012233B CN 201510519443 A CN201510519443 A CN 201510519443A CN 105012233 B CN105012233 B CN 105012233B
- Authority
- CN
- China
- Prior art keywords
- procaine
- injection
- give
- composition
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 title claims abstract description 70
- 229960004919 procaine Drugs 0.000 title claims abstract description 69
- 239000000203 mixture Substances 0.000 title claims abstract description 53
- 238000002360 preparation method Methods 0.000 title claims description 27
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims abstract description 55
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 claims abstract description 54
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 44
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 41
- 238000002347 injection Methods 0.000 claims abstract description 33
- 239000007924 injection Substances 0.000 claims abstract description 33
- 239000008215 water for injection Substances 0.000 claims abstract description 31
- 239000003814 drug Substances 0.000 claims abstract description 23
- 239000011780 sodium chloride Substances 0.000 claims abstract description 22
- 229930003347 Atropine Natural products 0.000 claims abstract description 21
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 claims abstract description 21
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 claims abstract description 21
- 229960000396 atropine Drugs 0.000 claims abstract description 21
- 229960002428 fentanyl Drugs 0.000 claims abstract description 20
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000007788 liquid Substances 0.000 claims description 24
- 238000003756 stirring Methods 0.000 claims description 22
- 150000003839 salts Chemical class 0.000 claims description 15
- 230000001954 sterilising effect Effects 0.000 claims description 13
- 229940079593 drug Drugs 0.000 claims description 10
- 239000003610 charcoal Substances 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 8
- 238000011049 filling Methods 0.000 claims description 8
- 238000009472 formulation Methods 0.000 claims description 7
- 238000007789 sealing Methods 0.000 claims description 7
- 229960002668 sodium chloride Drugs 0.000 claims description 7
- 210000003205 muscle Anatomy 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 238000005660 chlorination reaction Methods 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 230000000149 penetrating effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 14
- 239000008280 blood Substances 0.000 abstract description 9
- 210000004369 blood Anatomy 0.000 abstract description 9
- 208000002193 Pain Diseases 0.000 abstract description 8
- 230000036407 pain Effects 0.000 abstract description 8
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 abstract description 7
- 231100000331 toxic Toxicity 0.000 abstract description 7
- 230000002588 toxic effect Effects 0.000 abstract description 7
- 230000032696 parturition Effects 0.000 abstract description 5
- 230000009471 action Effects 0.000 abstract description 4
- 230000000202 analgesic effect Effects 0.000 abstract description 4
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 230000029058 respiratory gaseous exchange Effects 0.000 abstract description 3
- 230000001629 suppression Effects 0.000 abstract description 3
- 229940090044 injection Drugs 0.000 description 21
- 206010002091 Anaesthesia Diseases 0.000 description 7
- 230000037005 anaesthesia Effects 0.000 description 7
- 210000004204 blood vessel Anatomy 0.000 description 7
- 238000001914 filtration Methods 0.000 description 6
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 5
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical group NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 4
- 208000007914 Labor Pain Diseases 0.000 description 4
- 208000035945 Labour pain Diseases 0.000 description 4
- 230000036592 analgesia Effects 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 230000035606 childbirth Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 208000030961 allergic reaction Diseases 0.000 description 2
- 229960004050 aminobenzoic acid Drugs 0.000 description 2
- 238000001949 anaesthesia Methods 0.000 description 2
- 239000002643 anesthesia adjuvant Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 239000003589 local anesthetic agent Substances 0.000 description 2
- 229960005015 local anesthetics Drugs 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 206010001497 Agitation Diseases 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 241001106067 Atropa Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 208000034423 Delivery Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- HCBIBCJNVBAKAB-UHFFFAOYSA-N Procaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 HCBIBCJNVBAKAB-UHFFFAOYSA-N 0.000 description 1
- 238000003723 Smelting Methods 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 241000208292 Solanaceae Species 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 208000030281 cervical edema Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000002999 depolarising effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- RMEDXOLNCUSCGS-UHFFFAOYSA-N droperidol Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CC=C(N2C(NC3=CC=CC=C32)=O)CC1 RMEDXOLNCUSCGS-UHFFFAOYSA-N 0.000 description 1
- 229960000394 droperidol Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 231100000284 endotoxic Toxicity 0.000 description 1
- 230000002346 endotoxic effect Effects 0.000 description 1
- 229940089602 epinephrine injection Drugs 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229940034192 fentanyl 0.04 mg Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000010247 heart contraction Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000001819 pancreatic juice Anatomy 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229960001309 procaine hydrochloride Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 230000036301 sexual development Effects 0.000 description 1
- 208000004003 siderosis Diseases 0.000 description 1
- 210000001013 sinoatrial node Anatomy 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000009677 vaginal delivery Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
组别 | 药物类别 | 病例数 | 产妇自我状况评价 |
对照组 | 其他用于减少分娩疼痛的方法 | 200人 | 60%的人认为采用其他减少分娩疼痛的药物,效果不理想,持续时间较短。 |
实验组 | 本发明组合物 | 200人 | 97%的人认为用本发明可以有减少疼痛感。 |
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510519443.6A CN105012233B (zh) | 2015-08-24 | 2015-08-24 | 一种含有普鲁卡因的用于分娩的组合物及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510519443.6A CN105012233B (zh) | 2015-08-24 | 2015-08-24 | 一种含有普鲁卡因的用于分娩的组合物及制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105012233A CN105012233A (zh) | 2015-11-04 |
CN105012233B true CN105012233B (zh) | 2018-04-20 |
Family
ID=54402792
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510519443.6A Active CN105012233B (zh) | 2015-08-24 | 2015-08-24 | 一种含有普鲁卡因的用于分娩的组合物及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105012233B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114099526A (zh) * | 2021-11-12 | 2022-03-01 | 黑龙江中医药大学 | 一种多囊卵巢综合征术后护理抗炎镇痛药物及其制备方法 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB805524A (en) * | 1955-10-03 | 1958-12-10 | Samuel David Goldberg | Improvements in or relating to local anesthetic compositions |
CN1095924A (zh) * | 1993-05-31 | 1994-12-07 | 王建松 | 一种治疗软组织损伤的复方注射液 |
CN102058523A (zh) * | 2009-11-13 | 2011-05-18 | 天津金世制药有限公司 | 一种普鲁卡因注射液 |
CN102159183A (zh) * | 2007-11-06 | 2011-08-17 | 斯图亚特·L·韦格 | 麻醉药组合物、制剂和使用方法 |
CN102366399A (zh) * | 2011-09-28 | 2012-03-07 | 河南辅仁怀庆堂制药有限公司 | 盐酸普鲁卡因注射液及其生产工艺 |
CN103720648A (zh) * | 2013-12-26 | 2014-04-16 | 辰欣药业股份有限公司 | 一种含盐酸甲哌卡因的水针剂及其制备方法 |
CN104146954A (zh) * | 2014-08-29 | 2014-11-19 | 广东埃纳生医疗投资发展有限公司 | 一种复合局麻药及其注射剂的制备方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050176823A1 (en) * | 2004-02-10 | 2005-08-11 | Diaz Robert L. | Intra-operative procedure for post-operative pain control |
-
2015
- 2015-08-24 CN CN201510519443.6A patent/CN105012233B/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB805524A (en) * | 1955-10-03 | 1958-12-10 | Samuel David Goldberg | Improvements in or relating to local anesthetic compositions |
CN1095924A (zh) * | 1993-05-31 | 1994-12-07 | 王建松 | 一种治疗软组织损伤的复方注射液 |
CN102159183A (zh) * | 2007-11-06 | 2011-08-17 | 斯图亚特·L·韦格 | 麻醉药组合物、制剂和使用方法 |
CN102058523A (zh) * | 2009-11-13 | 2011-05-18 | 天津金世制药有限公司 | 一种普鲁卡因注射液 |
CN102366399A (zh) * | 2011-09-28 | 2012-03-07 | 河南辅仁怀庆堂制药有限公司 | 盐酸普鲁卡因注射液及其生产工艺 |
CN103720648A (zh) * | 2013-12-26 | 2014-04-16 | 辰欣药业股份有限公司 | 一种含盐酸甲哌卡因的水针剂及其制备方法 |
CN104146954A (zh) * | 2014-08-29 | 2014-11-19 | 广东埃纳生医疗投资发展有限公司 | 一种复合局麻药及其注射剂的制备方法 |
Non-Patent Citations (1)
Title |
---|
阿托品、普鲁卡因宫颈封闭促产程活跃期进展145例报告;宋秀凤;《福建医药杂志》;19960531;第18卷(第5期);第120页左栏倒数第1,2段,右栏第1段,第121页左栏第1段 * |
Also Published As
Publication number | Publication date |
---|---|
CN105012233A (zh) | 2015-11-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102093872B1 (ko) | 지방제거용 주사제 조성물 및 이의 제조방법 | |
DE69828881T2 (de) | Zusammensetzung zur linderung von störungen der stimmungslage bei gesunden individuen | |
DE69934305T2 (de) | Verwendung von dexmedetomidine zur sedierung auf der intensivstation | |
EP1703913B1 (en) | Use of ribose in recovery from anaesthesia | |
KR101800851B1 (ko) | 국소 마취제 작용 시간 연장 진통제 | |
JPH01503146A (ja) | 身体組織の治療方法および身体組織への医薬の投与方法 | |
Friedman et al. | Adverse reactions to meprobamate | |
CN105012233B (zh) | 一种含有普鲁卡因的用于分娩的组合物及制备方法 | |
RU2152215C1 (ru) | Применение ропивакаина при изготовлении фармацевтического препарата с анальгезирующим действием с минимальной моторной блокадой | |
CN1067577C (zh) | 一种参麦大输液制备方法 | |
RU2699222C1 (ru) | Солевой электролитный раствор для проведения энтеральных инфузий | |
CN105748520A (zh) | 一种用于治疗缺血性视神经病变的复方制剂及其制备方法 | |
CN108992549A (zh) | 一种药物组合物及其制备方法、应用 | |
Vogt et al. | A preoperative retrobulbar block in patients undergoing scleral buckling reduces pain, endogenous stress response, and improves vigilance | |
Fitrisyah et al. | Laparoscopic Cholecystectomy under Segmental Thoracic Spinal Anesthesia | |
AU2012276476A1 (en) | Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation | |
Fitrisyah et al. | Archives of The Medicine and | |
CN106727605B (zh) | 环维黄杨星d在制备预防或治疗缺血性脑卒中药物中的应用 | |
Doggrell | Introduction to pharmacology, and routes of drugs administration and absorption | |
US5320601A (en) | Method for treatment of cholelithiasis and chronic hepato- and cholecystopathies secondary to said disease | |
RU2403918C1 (ru) | Способ лечения в послеоперационном периоде больных, прооперированных по поводу кишечной непроходимости | |
WO2021187968A1 (ru) | Фармацевтический набор и способ лечения воспалительных процессов | |
Lin et al. | Cardiovascular complications resulting from topical lidocaine application | |
RU2589260C1 (ru) | Капли плетнева, обладающие коагулирующим действием, и способ лечения тромбоцитопении при заболеваниях печени и лейкозах | |
CN110721310A (zh) | 一种药物组合物在制备治疗急性出血性脑损伤的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20211119 Address after: Room 419, building a, management committee of Dongying Economic and Technological Development Zone, No. 59, Fuqian street, Dongying District, Dongying City, Shandong Province, 257100 Patentee after: Dongying dongkai New Material Industrial Park Co.,Ltd. Address before: 276000 Department of Obstetrics and Gynecology, Affiliated Hospital of Shandong Medical College, No. 80 Jintan Road, Lanshan District, Linyi City, Shandong Province Patentee before: Duan Pengjing |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230103 Address after: 257091 Room 101, Building 5, Science and Technology Enterprise Accelerator, No. 17, Xinghuahe Road, Dongying Development Zone, Shandong Province Patentee after: Dongying Dongkai New Material Technology Research and Development Co.,Ltd. Address before: Room 419, building a, management committee of Dongying Economic and Technological Development Zone, No. 59, Fuqian street, Dongying District, Dongying City, Shandong Province, 257100 Patentee before: Dongying dongkai New Material Industrial Park Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240131 Address after: Room 405, Building A, Technology Enterprise Accelerator, No. 17 Xinghuahe Road, Development Zone, Dongying City, Shandong Province, 257091 Patentee after: Dongying Dongkai Industrial Park Operation Management Co.,Ltd. Country or region after: China Address before: 257091 Room 101, Building 5, Science and Technology Enterprise Accelerator, No. 17, Xinghuahe Road, Dongying Development Zone, Shandong Province Patentee before: Dongying Dongkai New Material Technology Research and Development Co.,Ltd. Country or region before: China |